SCHEMBL9921348

SCHEMBL9921348

Nc1ccc(C(=O)NNC(=O)c2ccc(N)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.64
TDP1 Q9NUW8 2/20 0.64
LMNA P02545 2/20 0.64
MEN1 O00255 1/20 0.64
PKM P14618 1/20 0.64
APEX1 P27695 1/20 0.64
KMT2A Q03164 1/20 0.64
ALDH1A1 P00352 3/20 0.58
GAA P10253 1/20 0.58
MAPT P10636 3/20 0.57
HIF1A Q16665 2/20 0.57
KDM4E B2RXH2 2/20 0.57
SLC22A6 Q4U2R8 1/20 0.57
SLC22A8 Q8TCC7 1/20 0.57
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
CTDSP1 Q9GZU7 1/20 0.52
PTGS1 P23219 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CYP3A4 P08684 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29949183 0.91 ALDH1A1 (0.56) POLBTDP1LMNAMEN1PKM
SCHEMBL1913559 0.89 MAOA (0.62) POLBTDP1LMNAMEN1PKM
SCHEMBL7863938 0.89 TP53 (0.60) POLBTDP1LMNAMEN1PKM
SCHEMBL15964221 0.89 ALDH1A1 (0.79) POLBTDP1LMNAMEN1PKM
SCHEMBL5464442 0.87 APEX1 (0.52) POLBTDP1LMNAMEN1PKM
SCHEMBL23918991 0.84 LMNA (0.64) POLBTDP1LMNAMEN1PKM
SCHEMBL16312774 0.83 LMNA (0.52) POLBTDP1LMNAMEN1PKM
SCHEMBL328628 0.82 HIF1A (0.67) POLBTDP1LMNAMEN1PKM
SCHEMBL297618 0.82 MEN1 (0.61) POLBTDP1LMNAMEN1PKM
SCHEMBL16336479 0.80 LMNA (0.59) POLBTDP1LMNAMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109053662-B Hypochlorite responsive hydrazono linkage and uses thereof 中国药科大学 2022-03-25 CN disclosed
US-9169339-B2 Curable composition, molded product and method for producing molded product DAIKIN INDUSTRIES, LTD. (JP) 2015-10-27 US disclosed
US-9169339-B2 Curable composition, molded product and method for producing molded product DAIKIN INDUSTRIES, LTD. (JP) 2015-10-27 US disclosed
US-20140235604-A1 COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-08-21 US disclosed
US-20130190456-A1 CURABLE COMPOSITION, MOLDED ARTICLE AND METHOD FOR PRODUCING MOLDED ARTICLE DAIKIN INDUSTRIES, LTD. (JP) 2013-07-25 US disclosed
US-20130190456-A1 CURABLE COMPOSITION, MOLDED ARTICLE AND METHOD FOR PRODUCING MOLDED ARTICLE DAIKIN INDUSTRIES, LTD. (JP) 2013-07-25 US disclosed
WO-2012077583-A1 CURABLE COMPOSITION, MOLDED PRODUCT AND METHOD FOR PRODUCING MOLDED PRODUCT DAIKIN INDUSTRIES, LTD. (JP) 2012-06-14 WO disclosed
US-3971805-A Iminoisoindolinone pigments and process for their manufacture CIBA-GEIGY CORPORATION (US) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235604-A1 COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS ALDH1A2, NR2E3, LRAT POLB 2624/4885TDP1 1903/4885LMNA 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.